PL3183236T3 - Sposób wytwarzania 18f-znakowanych aktywnych estrów i ich zastosowanie na przykładzie wytwarzania znacznika pet specyficznego dla psma - Google Patents

Sposób wytwarzania 18f-znakowanych aktywnych estrów i ich zastosowanie na przykładzie wytwarzania znacznika pet specyficznego dla psma

Info

Publication number
PL3183236T3
PL3183236T3 PL15753692.1T PL15753692T PL3183236T3 PL 3183236 T3 PL3183236 T3 PL 3183236T3 PL 15753692 T PL15753692 T PL 15753692T PL 3183236 T3 PL3183236 T3 PL 3183236T3
Authority
PL
Poland
Prior art keywords
psma
tracer
preparation
production
active esters
Prior art date
Application number
PL15753692.1T
Other languages
English (en)
Inventor
Bernd Neumaier
Boris Zlatopolskiy
Raphael RICHARZ
Phillip KRAPF
Original Assignee
Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften
Universität Zu Köln
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53938345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3183236(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP14183635.3A external-priority patent/EP2993171A1/en
Application filed by Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften, Universität Zu Köln filed Critical Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften
Publication of PL3183236T3 publication Critical patent/PL3183236T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13Labelling of peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL15753692.1T 2014-08-24 2015-08-24 Sposób wytwarzania 18f-znakowanych aktywnych estrów i ich zastosowanie na przykładzie wytwarzania znacznika pet specyficznego dla psma PL3183236T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14182053 2014-08-24
EP14183635.3A EP2993171A1 (en) 2014-09-04 2014-09-04 Method for the production of 18F-labeled PSMA-specific PET-tracers
PCT/EP2015/069356 WO2016030329A1 (en) 2014-08-24 2015-08-24 Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer

Publications (1)

Publication Number Publication Date
PL3183236T3 true PL3183236T3 (pl) 2022-07-18

Family

ID=53938345

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15753692.1T PL3183236T3 (pl) 2014-08-24 2015-08-24 Sposób wytwarzania 18f-znakowanych aktywnych estrów i ich zastosowanie na przykładzie wytwarzania znacznika pet specyficznego dla psma

Country Status (5)

Country Link
US (1) US10112974B2 (pl)
EP (1) EP3183236B1 (pl)
ES (1) ES2912753T3 (pl)
PL (1) PL3183236T3 (pl)
WO (1) WO2016030329A1 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EA201590783A1 (ru) 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3533473A3 (en) 2013-11-14 2019-12-18 Endocyte, Inc. Compounds for positron emission tomography
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
KR102233726B1 (ko) 2015-09-30 2021-03-31 도이체스 크렙스포르슝스첸트룸 전립선 특이적 막 항원(psma)의 18f-태그된 저해제 및 전립선암에 대한 조영제로서 이의 용도
GB201518918D0 (en) 2015-10-26 2015-12-09 Norsk Medisinsk Syklotronsenter As And Uni I Oslo Method
RS65188B1 (sr) * 2016-03-22 2024-03-29 Univ Johns Hopkins Sredstva sa visokim afinitetom za ciljano dejstvo na membranski antigen specifičan za prostatu za endoradioterapiju kancera prostate
DK3481804T3 (da) 2016-06-10 2025-01-13 Univ Johns Hopkins Forbedret syntese af radioaktivt mærket hæmmer af prostataspecifikt membranantigen (PSMA) [18F]DCFPyL
WO2018022603A1 (en) * 2016-07-25 2018-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of making 18f-labeled precursors and peptides, labeled c-met binding peptides, and methods of use thereof
AU2017311510B2 (en) 2016-08-10 2021-11-18 Cancer Targeted Technology Llc Chelated PSMA inhibitors
AU2017348111B2 (en) 2016-10-27 2023-04-06 Progenics Pharmaceuticals, Inc. Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications
DE102016122273B4 (de) 2016-11-18 2018-06-21 Abx Advanced Biochemical Compounds Gmbh Präkursoren für die Radiofluorierung
MX2019005742A (es) * 2016-11-23 2019-09-13 Cancer Targeted Tech Llc Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.
US11628229B2 (en) * 2017-03-13 2023-04-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Method of synthesizing 18F radiolabeled biomolecular agents
CN111032632B (zh) * 2017-05-30 2024-04-12 约翰霍普金斯大学 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂
US12602772B2 (en) 2018-01-08 2026-04-14 Progenics Pharmaceuticals, Inc. Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination
EP3765097B1 (en) 2018-03-16 2022-04-27 Universität zu Köln 2-alkoxy-6-[18f]fluoronicotinoyl substituted lys-c(o)-glu derivatives as efficient probes for imaging of psma expressing tissues
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
EP4597424A3 (en) 2019-01-07 2025-10-29 Exini Diagnostics AB Systems and methods for platform agnostic whole body image segmentation
BR112021021011A2 (pt) 2019-04-24 2021-12-14 Exini Diagnostics Ab Sistemas e métodos para análise automatizada e interativa de imagens de varredura óssea para detecção de metástases
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
US12417533B2 (en) 2019-09-27 2025-09-16 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
WO2021230184A1 (ja) * 2020-05-11 2021-11-18 学校法人 関西大学 化合物及びその製造方法、酸発生剤、組成物、レジスト膜、下層膜、パターン形成方法、及び光学物品
CN111548305B (zh) * 2020-05-12 2021-08-31 北京师范大学 一种可用于靶向psma的喹啉类化合物及其制备方法
CA3231578A1 (en) 2021-10-08 2023-04-13 Exini Diagnostics Ab Systems and methods for automated identification and classification of lesions in local lymph and distant metastases
CN114671806B (zh) * 2022-04-08 2024-03-01 上海如絮生物科技有限公司 一种亲水性吡啶衍生物、中间体、其制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2097111B1 (en) 2006-11-08 2015-07-15 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
ES2700234T3 (es) 2007-06-26 2019-02-14 Univ Johns Hopkins Inhibidores marcados del antígeno de membrana específico de la próstata (PSMA), evaluación biológica y uso como agentes para la obtención de imágenes
EP2062630A1 (en) 2007-11-20 2009-05-27 Trasis S.A. Method for the direct elution of reactive 18F fluoride from an anion exchange resin in an organic medium by the use of strong organic bases
PT2318366T (pt) 2008-08-01 2017-08-02 Univ Johns Hopkins Agentes de ligação a psma e suas utilizações
US9056841B2 (en) 2009-03-19 2015-06-16 The Johns Hopkins University PSMA-targeting compounds and uses thereof
GB0905438D0 (en) * 2009-03-30 2009-05-13 Ge Healthcare Ltd Radiolabelling reagents and methods

Also Published As

Publication number Publication date
ES2912753T3 (es) 2022-05-27
EP3183236B1 (en) 2022-04-20
WO2016030329A1 (en) 2016-03-03
US20170267717A1 (en) 2017-09-21
US10112974B2 (en) 2018-10-30
EP3183236A1 (en) 2017-06-28

Similar Documents

Publication Publication Date Title
PL3183236T3 (pl) Sposób wytwarzania 18f-znakowanych aktywnych estrów i ich zastosowanie na przykładzie wytwarzania znacznika pet specyficznego dla psma
IL250511A0 (en) Crystalline forms of ibrutinib
IL249968B (en) Preparation of a test site
HUE042409T2 (hu) Eljárás diaril-tiohidantoin vegyület elõállítására
SG10201601042PA (en) Production of ester mixtures
IL249663A0 (en) Process for the preparation of substituted oxiranes and triazoles
HUP1400475A2 (en) Novel process for preparation of treprostinil and its salts
PL3199161T3 (pl) Preparat farmaceutyczny
ZA201605103B (en) Administration of tasimelteon under fasted conditions
HUE042349T2 (hu) Eljárás diariltiohidantoin vegyület elõállítására
PL3110249T3 (pl) Sposób wytwarzania mikrokapsułek biobójczych
SI3189045T1 (sl) Nove soli nilotiniba in njih polimorfi
ZA201707704B (en) Production of vcl4
IL252461B (en) Alpha-asrylaldehyde ester, a method for its preparation and application
EP3181125C0 (en) CAPSULE FORMULATION
SG11201505385VA (en) Pharmaceutical composition in the form of a tabletand a method for producing same
SG11201608422VA (en) Phenanthroline phosphonic acid derivative and preparation method therefor and application thereof
IL249130B (en) Preparation of piperidine-4-carbothioamide
EP3221320A4 (en) A process for the preparation of ibrutinib
PL2977373T3 (pl) Sposób katalitycznego wytwarzania estrów
IL237572A0 (en) Process and intermediates for the preparation of dastinib
IL251099A0 (en) A salt of phenylglycine methyl ester
GB2544228B (en) Production Method of Joint Material
LT3393246T (lt) Chelanto gamybos būdas
TWM490349U (en) Improved structure of a darter